EZH2 and neoplasm: Ratnam and colleagues found that blocking EZH2 activity in human GBM cells with GSK126, a global EZH2 methyltransferase inhibitor with good BBB penetrance, led to upregulation of CXCL9 and CXCL10 chemokines and subsequently elevated tumor infiltrating T cells [2,33].